Gilead Sciences

Delays in the initiation of antiretroviral therapy remain a key challenge in the effort to help end the #HIV epidemic. But what do people living with HIV think about earlier initiation of treatment? Our new global survey – highlighting the experiences of 2,532 people living with HIV from 11 countries – reveals that nearly 40% of respondents waited more than 30 days following a diagnosis to start treatment. Yet, rapid initiation can lead to an undetectable viral load sooner, reducing the risk of transmission and improving overall health outcomes. How can we help bridge this gap? By engaging, listening and responding to the real-world needs of people and communities affected by HIV. Learn more about our person-centric approach and research at #IAS2025. https://gilead.inc/4nVbbsU

Last week, 75 students from across San Mateo County participated in a campus tour and career panel discussion with Gilead employees at our Foster City campus. The Gilead Foundation partnered with the San Mateo County Office of Education, as part of their Youth Empowerment, Entrepreneurship, and Employment Program, to highlight career paths in STEM and give a firsthand look at what it's like to work at Gilead. This is part of our broader efforts to support programs in healthcare education, access and leadership development. #GileadLife

At Gilead, our focus is on turning scientific innovation into real-world impact. We’re committed to delivering our medicines to people who need them most, and our recent agreement with The Global Fund will help expand access to our #HIV prevention medicine once approved in high-incidence, resource-limited countries. #IAS2025

Yvette Raphael played a pivotal role in Gilead’s #HIV prevention trials, ensuring that the voices of young women and adolescent girls were not only heard, but prioritized. Alongside Moupali Das and others, she worked to build a blueprint to help inform the future of HIV innovation. Inclusion in clinical trials is essential — not just for advancing science, but for ensuring that HIV treatment and prevention strategies help meet the needs of all communities. When women are represented in research, outcomes improve for everyone. #IAS2025 

#InTheNews: Researchers at Penn Medicine, University of Pennsylvania Health System are exploring how CAR T-cell therapy might one day help patients with aggressive brain cancers like #glioblastoma. While this treatment is still under investigation for brain tumors, the research offers hope for future advances in treatment. We’re proud to collaborate with Penn Medicine to help discover the next generation of emerging therapeutic options for patients. http://bit.ly/4kx81sA #GBMDay

We’re announcing interim results from our new global survey, which once complete, will be one of the largest global surveys of people living with #HIV. Co-created with community representatives from around the world, this survey includes 2,532 participants across 11 countries and amplifies the experiences of people living with HIV – many from underrepresented groups.   The key findings highlight priorities for the broad range of people and communities affected by HIV:  🌍 The need for earlier initiation of antiretroviral therapy   🌍 The importance of person-centered care and treatment choices   🌍 The ongoing work required to reduce HIV-related stigma  At Gilead, we’re committed to putting people at the center of HIV care. Learn more: http://gilead.inc/3TC9DpY #IAS2025 

Scientific progress is measured in more than data points. It’s measured in the people reached, the questions answered and the impact made. From diverse clinical trials to advances in virology, oncology and inflammation, these numbers reflect the real-world progress behind our work. Because at Gilead, we innovate for impact. Read more in our 2024 Responsible Business and Impact Report: https://gilead.inc/3Eu4JHC

Helping end the HIV epidemic means listening to the real experiences and needs of people living with HIV as well as those who need PrEP (pre-exposure prophylaxis). That's why we’re focused on developing innovative solutions, expanding access to care and working closely with communities to help ensure that no one is left behind. Every step we take is guided by the goal of making a tangible difference for those affected by #HIV. At #IAS2025, we’re proud to join global industry leaders to share our progress and reinforce our commitment to accessible, transformative care that helps people get the support they need.  

#GileadNews: We’re presenting new data at #IAS2025 on the safety and efficacy of our #HIV prevention medication across underrepresented populations, including pregnant and lactating women and young people. This person-centered, inclusive research is part of our ambition to help meet people where they are. Read more: https://gilead.inc/4kzk5cV

#GileadNews: Today, the World Health Organization (WHO) issued new guidelines for the use of our long-acting #HIV prevention medication, as well as new HIV testing protocols for long-acting prevention medications. These new guidelines help to align global stakeholders and inform decision making as we strive to help transform the HIV prevention landscape. Read more: https://gilead.inc/40MiDMX